Company contact: Maria Maccecchini, CEO
QR Pharma, Inc.
484 253 2296
Maccecchini@qrpharma.com

QR Pharma to Present at BIO-Windhover Conference
/Pharmaceutical Strategic Outlook 2011

Radnor, PA, March 31, 2011 QR Pharma, Inca developer of novel compounds to treat Alzheimer's disease and neurodegenerative disorders, announced today that Dr. Maria Maccecchini, chief executive officer, is scheduled to speak at the BIO-Windhover/Pharmaceutical Strategic Outlook conference in New York City, NY. Dr. Maccecchini will provide a corporate overview and update on the company's development programs in AD. The presentation will be held on Thursday, March 31, 2011, at 4:00 PM at the Grand Hyatt Hotel.

About Posiphen®, QR's Lead Compound
Posiphen® is in clinical development as an oral treatment for Alzheimer's disease. It is a small orally active compound with high blood brain barrier permeability, which lowers amyloid precursor protein (APP) levels. Posiphen reduces the rate of synthesis of APP in cell cultures, normal, transgenic and trisomic mice. APP is cleaved into a number of toxic peptides, including Aβ42, which is cleaved from the middle while the others are cleaved from the N- and C- terminal ends. These peptides attack multiple pathways of neuronal cell life leading to synaptic loss and nerve cell death. This degeneration of the brain induces dysfunction, neuroinflammation and leads to cognitive impairment and neurodegeneration.

QR conducted a trial in patients with mild cognitive impairment to confirm Posiphen's mechanism of action in humans and correlate it with the pharmacokinetics of the compound and its metabolites in CSF and plasma. Posiphen lowers levels of APP and tau by about 40%, approaching the levels found in healthy volunteers.

About QR Pharma, Inc.
Headquartered in Radnor, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment, Alzheimer's disease, Parkinson's disease and Down syndrome. QR currently has two product development programs - Posiphen for early stage AD and BNC for advanced AD. For more information on QR Pharma, please visit the company's website, www.qrpharma.com.

Contact: Claudia Muntean, MBA
Tel: 610 209 8454
Fax: 484 253 2288
muntean@qrpharma.com
www.qrpharma.com